Drugs / sacubitril/valsartan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02788656 | Sep 2016 → Nov 2018 | congestive heart failure | Brigham and Women's Hospital | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-03-31 | Novartis Pharmaceuticals | Regulatory Novartis Entresto receives positive CHMP opinion for pediatric heart failure novartis.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-03-31 | Novartis Pharmaceuticals | Novartis Entresto receives positive CHMP opinion for pediatric heart failure novartis.com ↗ |
| 2018-08-25 | Novartis Pharmaceuticals | Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode novartis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sacubitril/valsartan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02788656 ↗ |
| Action | Inhibit | “sacubitril, an inhibitor of neprilysin” NCT02788656 ↗ |